SAB Biotherapeutics Inc. (SABSW)
SAB Biotherapeutics Statistics
Share Statistics
SAB Biotherapeutics has 9.29M shares outstanding. The number of shares has increased by -99.14% in one year.
Shares Outstanding | 9.29M |
Shares Change (YoY) | -99.14% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 9.5% |
Shares Floating | 7.49M |
Failed to Deliver (FTD) Shares | 1.05K |
FTD / Avg. Volume | 4.56% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
Short Interest | 0 |
Short % of Shares Out | 0% |
Short % of Float | 0% |
Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.02 and the forward PE ratio is null. SAB Biotherapeutics's PEG ratio is 0.
PE Ratio | -0.02 |
Forward PE | n/a |
PS Ratio | 0.53 |
Forward PS | 0.3 |
PB Ratio | 0.03 |
P/FCF Ratio | -0.02 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.18.
Current Ratio | 2.98 |
Quick Ratio | 2.98 |
Debt / Equity | 0.18 |
Debt / EBITDA | -0.11 |
Debt / FCF | -0.14 |
Interest Coverage | 134.77 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $23.2K |
Profits Per Employee | $-598.34K |
Employee Count | 57 |
Asset Turnover | 0.03 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -0.34% in the last 52 weeks. The beta is 0.45, so SAB Biotherapeutics's price volatility has been higher than the market average.
Beta | 0.45 |
52-Week Price Change | -0.34% |
50-Day Moving Average | 0.05 |
200-Day Moving Average | 0.05 |
Relative Strength Index (RSI) | 41.79 |
Average Volume (20 Days) | 23.07K |
Income Statement
In the last 12 months, SAB Biotherapeutics had revenue of 1.32M and earned -34.11M in profits. Earnings per share was -3.68.
Revenue | 1.32M |
Gross Profit | 1.32M |
Operating Income | -42.91M |
Net Income | -34.11M |
EBITDA | -42.91M |
EBIT | -34.42M |
Earnings Per Share (EPS) | -3.68 |
Balance Sheet
The company has 8.9M in cash and 4.67M in debt, giving a net cash position of 4.23M.
Cash & Cash Equivalents | 8.9M |
Total Debt | 4.67M |
Net Cash | 4.23M |
Retained Earnings | -124.17M |
Total Assets | 44.2M |
Working Capital | 15.81M |
Cash Flow
In the last 12 months, operating cash flow was -34.29M and capital expenditures 0, giving a free cash flow of -34.29M.
Operating Cash Flow | -34.29M |
Capital Expenditures | 0 |
Free Cash Flow | -34.29M |
FCF Per Share | -3.7 |
Margins
Gross margin is 100%, with operating and profit margins of -3244.87% and -2579.03%.
Gross Margin | 100% |
Operating Margin | -3244.87% |
Pretax Margin | -2579.03% |
Profit Margin | -2579.03% |
EBITDA Margin | -3244.87% |
EBIT Margin | -3244.87% |
FCF Margin | -2593.15% |
Dividends & Yields
SABSW does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SABSW.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | -6.03 |
Piotroski F-Score | 1 |